Palosuran Treatment Effective as Bosentan in the Treatment Model of Pulmonary Arterial Hypertension

Basit Öğe Kaydı
dc.authoridDokuyucu, Recep/0000-0001-7881-8871
dc.authoridKaplan, Davut Sinan/0000-0003-4663-209X
dc.authoridCeribasi, Ali Osman/0000-0002-6096-4042
dc.authoridDokuyucu, Recep/0000-0001-6837-3477
dc.authoridOrkmez, Mustafa/0000-0001-5255-0504
dc.contributor.authorPehlivan, Yavuz
dc.contributor.authorDokuyucu, Recep
dc.contributor.authorDemir, Tuncer
dc.contributor.authorKaplan, Davut Sinan
dc.contributor.authorKoc, Ibrahim
dc.contributor.authorOrkmez, Mustafa
dc.contributor.authorTurkbeyler, Ibrahim Halil
dc.date.accessioned2024-09-18T20:55:33Z
dc.date.available2024-09-18T20:55:33Z
dc.date.issued2014
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractPulmonary arterial hypertension (PAH) is a progressive and fatal disorder that any valuable advance in the management of diseases has crucial importance. The present study aimed to compare the Endothelin1 (ET1) inhibitor bosentan which is regarded as standard therapy with different dose regimens of palosuran which is urotensin-II (UII) inhibitor and explore the discrepancy for mean pulmonary arterial pressure (mPAP), UII, ET1 levels, and pulmonary vascular pathology. Seventy rats were randomly divided into seven groups of ten animals each: group 1 (control group) received the vehicle subcutaneously, instead of monocrotaline (MCT) and vehicle; group 2 (MCT group) received subcutaneous MCT and vehicle; and group 3 (MCT + palosuran 30 mg) received subcutaneous MCT and palosuran. Other groups consist of group 4 (MCT + palosuran 100 mg), group 5 (MCT + bosentan 30 mg), group 6 (MCT + bosentan 100 mg), and group 7 (combination therapy). Serum ET1, UII, mPAP levels, and pulmonary arteriolar pathology of different diameter vessels of all groups have been measured and recorded. The ET1 and UII levels of untreated rats (group 2) were significantly higher than the other groups (p < 0.05). Moreover, mPAP levels of group 2 were significantly higher than the other groups (p = 0.001). Finally, 50-125-mu m diameter of arteriole wall thickness was found to be significantly thicker in monocrotaline group compared to groups 4 and 6 (p < 0.001). Statistical differences of wall thickness/diameter ratios of arteries and arterioles larger than 125 was found to be significant between group 5, group 6, and the control group (p < 0.001). UII inhibitor is at least as effective as standard therapy bosentan. Findings of this study consolidate that palosuran could be a new future promising therapeutic option in PAH.en_US
dc.identifier.doi10.1007/s10753-014-9855-8
dc.identifier.endpage1288en_US
dc.identifier.issn0360-3997
dc.identifier.issn1573-2576
dc.identifier.issue4en_US
dc.identifier.pmid24604341en_US
dc.identifier.scopus2-s2.0-84904741048en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1280en_US
dc.identifier.urihttps://doi.org/10.1007/s10753-014-9855-8
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11912
dc.identifier.volume37en_US
dc.identifier.wosWOS:000338725600034en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer/Plenum Publishersen_US
dc.relation.ispartofInflammationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectpulmonary arterial hypertensionen_US
dc.subjecturotensin-II antagonisten_US
dc.subjectpalosuranen_US
dc.titlePalosuran Treatment Effective as Bosentan in the Treatment Model of Pulmonary Arterial Hypertensionen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
2.29 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu